Novo Nordisk A/S (NYSE:NVO) Shares Sold by QV Investors Inc.

QV Investors Inc. lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,274 shares of the company’s stock after selling 180 shares during the quarter. QV Investors Inc.’s holdings in Novo Nordisk A/S were worth $712,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Natixis Advisors LLC boosted its holdings in Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after acquiring an additional 19,870 shares in the last quarter. Versant Capital Management Inc acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $86,000. Zions Bancorporation N.A. lifted its stake in Novo Nordisk A/S by 57.0% during the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after purchasing an additional 6,726 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in Novo Nordisk A/S by 14.8% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after purchasing an additional 37,346 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NVO traded down $1.95 on Monday, hitting $84.31. 4,851,626 shares of the company traded hands, compared to its average volume of 7,036,448. Novo Nordisk A/S has a 12-month low of $81.50 and a 12-month high of $148.15. The company has a 50 day moving average of $100.35 and a 200-day moving average of $119.04. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $378.34 billion, a PE ratio of 27.28, a PEG ratio of 1.37 and a beta of 0.45.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.